Dai ichi Life Insurance Company Ltd Has $15.99 Million Holdings in Cencora, Inc. (NYSE:COR)

Dai ichi Life Insurance Company Ltd lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 11.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 71,046 shares of the company's stock after selling 9,619 shares during the quarter. Dai ichi Life Insurance Company Ltd's holdings in Cencora were worth $15,991,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BOKF NA purchased a new stake in Cencora during the 1st quarter worth about $260,000. SVB Wealth LLC purchased a new stake in Cencora in the 1st quarter valued at about $598,000. Silvercrest Asset Management Group LLC purchased a new stake in Cencora in the 1st quarter valued at about $7,976,000. Kennedy Capital Management LLC purchased a new stake in Cencora in the 1st quarter valued at about $705,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Cencora in the 1st quarter valued at about $2,194,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Price Performance

COR stock traded up $3.22 during trading hours on Tuesday, hitting $247.45. 399,146 shares of the stock traded hands, compared to its average volume of 1,395,977. The stock has a 50-day simple moving average of $233.28 and a 200 day simple moving average of $231.85. Cencora, Inc. has a one year low of $195.83 and a one year high of $251.56. The company has a market cap of $48.76 billion, a P/E ratio of 32.53, a P/E/G ratio of 1.63 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a $0.55 dividend. This is a positive change from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora's dividend payout ratio (DPR) is 29.29%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on COR shares. Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Bank of America reaffirmed a "neutral" rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Barclays lifted their price objective on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Finally, Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $271.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.